LivingGLP1
Study S000973

Tirzepatide Impact Assessment: Exploring Health and Wellness Outcomes

ClinicalTrials.gov record

Registration

Registration
NCT07740291
Acronym
TIA
Study type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Status
RECRUITING
Enrollment
27
Start
2025-01-02
Primary completion
2026-11-23
Lead sponsor
Texas Tech University
Conditions
Obesity & Overweight; Cardiometabolic Health Indicators; Addiction; Eating Disorders; Mental Health
Interventions
DRUG:GLP-1 Receptor Agonist Therapy; BEHAVIORAL:Structured Lifestyle Intervention
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in Fasting Blood Glucose [Baseline and 3 months]
  • Change in LDL Cholesterol [Baseline and 3 months]
  • Change in Triglycerides [Baseline and 3 months]
  • Change in Fasting Insulin [Baseline and 3 months]
  • Change in Blood Pressure [Baseline and 3 months]
  • Change in Disordered Eating [Baseline and 3 months]
  • Change in Food Addiction [Baseline and 3 months]
  • Change in Alcohol Use [Time Frame: Baseline and 3 months]
  • Change in Substance Use [Time Frame: Baseline and 3 months]
  • Change in Depressive Symptoms and Suicidal Ideation [Time Frame: Baseline and 3 months]
  • Change in Anxiety [Baseline and 3 months]
  • Change in Perceived Stress [Baseline and 3 months]
  • Change in Fatigue [Baseline and 3 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.